<DOC>
	<DOCNO>NCT02651740</DOCNO>
	<brief_summary>The purpose study evaluate efficacy well safety rifaximin fecal microbiota transplantation treatment IBS-D .</brief_summary>
	<brief_title>Gut Microbiota Reconstruction Treatment Diarrhea-predominant Irritable Bowel Syndrome</brief_title>
	<detailed_description>For IBS-D patient , rifaximin fecal microbiota transplantation give separately together order evaluate efficacy safety two therapy compare placebo .</detailed_description>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Diarrhea</mesh_term>
	<mesh_term>Irritable Bowel Syndrome</mesh_term>
	<mesh_term>Rifaximin</mesh_term>
	<mesh_term>Rifamycins</mesh_term>
	<criteria>Age 18 65 , gender limitation ; Had receive diagnosis IBSD ( assess accord Rome III diagnosis criterion IBS ) undergone colonoscopic examination within previous 2 year organic lesion observe ; Has current symptom IBSD : ①Abdominal pain ( rat average daily amount abdominal pain score 3 010 point score system week ( 0 indicate pain 10 great deal pain ) ) ; ② Stool consistency ( rat consistency stool Bristol type 6/7 ( loose watery ) least day least 2 day week ) ; Can followup required time point sign write informed consent study . Allergic rifaximin ; Taking alosetron , tegaserod , lubiprostone , warfarin , antipsychotic , antispasmodic , antidiarrheal , probiotic , narcotic drug within previous 1 month ; Had infective diarrhea history take antibiotic within previous 14 day ; Patients history inflammatory bowel disease ; Previous abdominal surgery ( cholecystectomy appendectomy ) ; Human immunodeficiency virus infection immunodeficiency condition congenital immunodeficiency currently take immunesuppression drug ; Unstable diabetes , hypertension , thyroid disease , etc ; Accompanied malignant tumor severe heart/lung/renal/hepatic/brain/blood disease ; Accompanied severe neural/psychotic disease epilepsy , depression , mania , schizophrenia , etc ; Other condition doctor think suitable study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>January 2016</verification_date>
	<keyword>Rifaximin</keyword>
	<keyword>Fecal microbiota transplantation</keyword>
</DOC>